C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2026)
C4 Therapeutics' (CCCC) quarterly Change in Account Payables came in at -$85000.0 in Q1 2026, up 86.82% year-on-year from -$45497.9 in Q1 2025, and up 81.99% quarter-over-quarter from -$472000.0 in Q4 2025.
C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2026) Analysis & Trends
C4 Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$85000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 86.82% year-over-year to -$85000.0 in Q1 2026; TTM through Mar 2026 was $92000.0, a 109.73% increase from a year earlier, with the FY2025 full-year figure at -$468000.0, down 293.28% from the prior year.
- Change in Account Payables climbed to -$85000.0 in Q1 2026 per CCCC's latest filing, from -$472000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.5 million in Q2 2025 and bottomed at -$1.7 million in Q3 2022.
- The 5-year median for Change in Account Payables is -$176000.0 (2024), against an average of -$219529.4.
- Biggest YoY gain for Change in Account Payables was 314.55% in 2025; the steepest drop was 454.4% in 2025.
- Year by year, Change in Account Payables stood at -$1.1 million in 2022, then surged by 115.71% to $169000.0 in 2023, then slumped by 204.14% to -$176000.0 in 2024, then plunged by 168.18% to -$472000.0 in 2025, then surged by 81.99% to -$85000.0 in 2026.
- Per Business Quant, the three latest CCCC Change in Account Payables figures stand at -$85000.0 (Q1 2026), -$472000.0 (Q4 2025), and -$885000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | -85,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85,000.00 |
| Mar 31, 2026 | -85,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Dec 31, 2025 | -472,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Sep 30, 2025 | -885,000.00 |
| Jun 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | -645,000.00 |
| Mar 31, 2025 | -645,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Dec 31, 2024 | -176,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Jun 30, 2024 | -715,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 169,000.00 |
| Dec 31, 2023 | 169,000.00 |